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Abstract The pyrrolidine-catalysed formation of novel diastereomeric C11-
acetone adducts was observed during the chromatographic purification of  
pyrrolobenzodiazepine (PBD) compounds in the presence of acetone. The 
mechanism of this reaction was explored, and the adducts obtained fully 
characterised. Talirine, the cytotoxic payload element of the Antibody-Drug 
Conjugate (ADC) vadastuximab talirine, was also found to form this adduct 
under similar conditions. A cellular cytotoxicity evaluation of the modified PBD 
compounds confirmed their lack of cytotoxicity, consistent with loss of the 
DNA-interactive N10-C11 imine functionality. As well as the new chemistry 
reported here, given the number of PBD-based ADCs presently in the clinic, 
this observation may be important for the larger scale manufacture of PBD-
based products.   
Key words Pyrrolobenzodiazepines, PBDs, Stork Enamine, DNA-Binding, 
Talirine, ADC.  
 
Originally discovered in Streptomyces bacteria, pyrrolo[2,1-
c][1,4]benzodiazepines (PBDs) and their derivatives are of 
interest as chemotherapeutic agents1. Examples of PBD 
structures include anthramycin, SJG-136 and talirine (Figure 1). 
One PBD-based agent, SJG-1362, reached Phase II clinical trials in 
ovarian cancer and leukaemia, and a clinical trial in canine 
lymphoma is still underway3. PBD dimers are also being used as 
cytotoxic payloads to attach to antibodies to form Antibody-Drug 
Conjugates (ADCs), and examples containing the PBD dimers 
talirine and tesirine are presently in the clinic4-6. The presence of 
an electrophilic imine/carbinolamine at the N10-C11 position of 
the PBD structure is regarded as essential for their biological 
activity. This ‘soft’ imine electrophile undergoes nucleophilic 
attack by the nucleophilic C2-NH2 groups of guanine bases within 
the DNA minor groove, forming covalent adducts (Figure 2)7-10. 
These adducts are thought to inhibit the activity of a number of 
DNA processing proteins including  RNA polymerase, 
endonucleases and transcription factors, ultimately leading to 
cell death11,12,13, 14.  
 
Figure 1  Structures of Anthramycin (1), a naturally occurring PBD monomer, 
and the synthetic PBD dimers SJG-136 (2) and talirine (3).  
 
Figure 2  Mechanism of binding of a PBD to the C2-amino group of a guanine 
base within the DNA minor groove. 
In addition to the significance of the N10-C11 imine moiety of the 
PBD core from a biological perspective, this inherently reactive 
functional group can also be manipulated synthetically in order 
to enhance stability or alter toxicity profiles. For example, water 
or methanol can add to the imine to form carbinolamine (4) or 
carbinolamine methyl ether (5) species, respectively. The former 
is thought to form in aqueous solution and has been postulated 
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to be the ultimate biologically active species for all PBD-based 
molecules (Figure 3)15.  The imine, carbinolamine and 
carbinolamine methyl ether forms have been shown to be 
interconvertible, and some PBDs are more stable in their methyl 
ether forms when stored in powder form (e.g., anthramycin 
methyl ether16).   
Recently, several groups have sought to reversibly modify the 
N10-C11 imine to develop more selectively targeted PBD pro-
drugs. Examples include the conjugation of enzymatically 
cleavable agents such as sugars17 and nitroimidazole carbamate18 
moieties to the N10-position of the imine.  Furthermore, in the 
construction of  ADCs containing PBD-based payloads, control of 
the reactivity of the N10-C11 imine is often important to improve 
overall stability and toxicity of the ADC. Accordingly, the antibody 
is sometimes connected to the PBD through a carbamate linkage 
to the N10-position, allowing release of the electrophilic N10-C11 
imine moiety only upon carbamate cleavage19. 
Irreversible modifications of the N10-C11 imine have also been 
reported. For example, thiol nucleophiles such as thiophenol and 
glutathione have also been shown to add to the C11-position of  
the imine functionality (e.g., 6)20, 21.  In the case of carbon 
nucleophiles, the stereoselective addition of an indole to the C11-
position of a PBD core structure has been reported by Mori and 
co-workers22 to produce the natural product tilivalline (7), a 
good example of the potential for modification and 
diversification at this position. Recently, the biosynthesis of this 
compound by Klebsiella oxytoca16 has been implicated as a 
possible cause of human antibiotic-associated colitis23  However, 
in comparison with traditional, imine-containing PBDs, 7 
displays relatively weak cytotoxicity24 which may derive from a 
non-DNA-binding mechanism.  The similarly synthesised C11-
cyano derivative (8)25 appears to be more cytotoxic, and may be 
able to convert to the N10-C11 imine form under biological 
conditions, although this has not been demonstrated 
experimentally. Therefore, based on the above, the formation of 
potentially irreversible C-C bonds at the C11-position of the PBD 
structure has been avoided in the development of PBD-based 
therapeutic agents in an effort to maintain DNA-binding 
properties and cytotoxicity. 
 
Figure 3 Examples of structures of products from the attack of various 
nucleophiles on the N10/C11-imine position of a PBD core, including  C11-
adducts formed from water (4), methanol (5) and thiophenol (6), the natural 
product tilivalline (7) and a C11-cyano-PBD derivative (8; major diastereomer 
shown). 
 
Here, we report that acetone can add to the C11-position of a PBD 
core via an apparent Stork enamine reaction.  This was initially 
observed to occur during the purification of PBD compounds by 
column chromatography when acetone was used as a component 
of the solvent system.  The acetone adducts are devoid of 
cytotoxicity due to the loss of the DNA-interactive N10-C11 imine 
moiety.  Therefore, the observation of this reaction has 
implications for the manufacture of PBD-based therapeutic 
agents, as well as being of chemical interest. 
PBDs are mostly synthesized via a multi-step route starting from 
commercially available building blocks such as vanillin and 
pyrrolidinemethanol, and many typical routes have been 
reported and reviewed15.  The N10-C11 imine moiety (in its 
carbinolamine form) is protected during a typical synthesis using 
Alloc (at the N10) and THP (at the C11) as protecting groups (e.g., 
9, Scheme 1).  In particular, the C11-O-THP protection avoids loss 
of the relatively vulnerable C11-OH group when exposed to 
numerous reagents during multistep synthetic routes1, 15. 
The final step of the synthesis involves removal of the N10-Alloc 
group via a palladium catalysed Tsuji-Trost reaction, using 
pyrrolidine as a nucleophile.  This leads to a concerted loss of the 
THP group to yield the imine 10 with typical yields of 70-80% 
(Scheme 1).  
 
Scheme 1 The final step of a commonly utilized synthetic route for PBDs.  The 
biologically-active N10-C11 imine functionality of 10 is produced through 
removal of the N10-allyl carbamate and C11-OTHP protecting groups of the 
penultimate intermediate 9. 
Progress of the reaction is typically monitored through TLC or 
HPLC-MS and, in order to remove the palladium catalyst and 
other impurities, flash column chromatography is frequently 
used.  In the observation reported here, a 
dichloromethane/acetone solvent system was used for the final 
purification of a PBD of type 9.  However, following purification 
of the concentrated reaction mixture after chromatography, an 
increase in mass was observed by HPLC-MS analysis, with two 
new compounds produced for which NMR analysis indicated a 
loss of the imine functionality.  Further chromatography allowed 
the two products to be isolated and characterised as the 
diastereomeric C11-acetone adducts 16 and 1726 (Scheme 2). 
 
Scheme 2 Proposed Stork enamine mechanism for the formation of the C11-
acetone adducts 16 and 17 from PBD imine 10. 
This proposed Stork enamine reaction mechanism is feasible 
because the unpurified PBD imine was exposed to residual 
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pyrrolidine during the final deprotection step.  The combination 
of acetone (used as a component of the eluent during 
chromatography) and pyrrolidine could generate a reactive 
enamine 14 which may act as a carbon nucleophile, attacking the 
PBD imine at the C11-position and forming intermediate 15.  
Subsequent hydrolysis of the enamine would yield the final 
products 16 and 17 as a mixture of two diastereomers.  One 
diastereomer (16) formed preferentially (i.e., ~70% of total 
product), although it was possible to separate both 
diastereomers by further flash column chromatography, 
obtaining compounds of identical molecular weight as identified 
by UPLC-MS (see S1, Supporting Information).  It proved difficult 
to conclusively confirm the diastereomeric ratio through NMR 
due to the complexity of the spectra.  However, based upon COSY 
NMR and the observed multiplicity of the C11a-proton (ddd, J = 
10.6, 8.9, 4.9 Hz, see S2, Supporting Information) in the NMR 
spectrum of the dominant diastereomer, it was evident that the 
C11(S)/C11a(S)-diastereomer forms preferentially. This would 
involve attack of the enamine from the most sterically-favoured 
direction, trans to the pyrrolidine ring of the PBD (see Figure 4). 
 
Figure 4 Rationalisation of the stereochemistry of the dominant diastereomer 
16 based on the most sterically-favoured approach of the nucleophile to PBD 
10 (R = CH2CH2CH2-COOCH3). The dotted line in the Newman Projection 
represents the pyrrolidine ring of the PBD. 
To provide more evidence for the proposed mechanism (i.e., 
Scheme 2), pyrrolidine (0.1 equiv.) was added to the purified PBD 
imine 10 dissolved in acetone. After 72 hours at room 
temperature, conversion to 16 and 17 in good yield (67% 
overall) was observed (see S3, Supporting Information).  The 
experiment was repeated in the presence of silica gel (0.05 
equiv.) to simulate the chromatographic conditions, however no 
significant difference in the rate or extent of formation of 16 and 
17 was observed, indicating that only pyrrolidine and acetone 
are required for reaction to occur.  
To investigate the vulnerability of more clinically-relevant PBD 
compounds to enamine attack, talirine (3, Figure 1), a PBD-based 
ADC payload of significant current clinical interest4-6, was 
exposed to similar acetone/pyrrolidine conditions.  Evidence of 
mono and bis acetone adducts were observed using LC-MS (see 
S4, Supporting Information). Given the asymmetric nature of this 
dimer molecule, up to eight possible adducts with different 
stereochemistries may have formed, and this mixture was too 
complex to resolve chromatographically.  An example of a 
potentially preferred adduct is shown in Figure 5. 
 
Figure 5 One of eight potential bis-acetone adducts of talirine (3) formed upon 
treatment with acetone/pyrrolidine. Acetone adducts may form at both N10-
C11 loci in either S or R configurations.  
   
Formation of 16 and 17 was similarly observed when piperidine 
was used in place of pyrrolidine, albeit in more modest yield 
(16%).  To eliminate the possibility that this reaction proceeded 
through the base catalysed enolization of acetone, pyrrolidine 
was substituted with the hindered base 2,2,6,6-
tetramethylpiperidine (TMP) of equal basicity. No formation of 
16 and 17 was observed in the presence of this base, suggesting 
that an enamine intermediate is required for adduct formation. 
Further reactions were attempted using more complex ketone 
structures as well as diethylamine and morpholine as base (see 
Table 1).  However, these reactions were unsuccessful, 
suggesting that acetone and pyrrolidine may be the optimal 
reagents. The lack of reactivity of the more complex ketones 
could be due to their increased steric bulk and/or lower 
nucleophilicity of their corresponding bases.  For example, it has 
been reported that morpholine-containing enamines 
consistently show poorer nucleophilicity compared to their 
pyrrolidine-containing counterparts 27.  
The major isolated diastereomer 16 and a 50:50 mixture of both 
diastereomers (16/17) were evaluated for cytotoxicity in a 
breast tumour cell line (MDA-MB-231) using the MTT assay (48 
hours incubation).  The unmodified imine-containing PBD 10 
was also evaluated as a control (Table 2; and S5, Supporting 
Information).  PBD 10 was cytotoxic in the low micromolar range, 
consistent with DNA-binding due to the presence of the N10-C11 
imine. In contrast, the C11-modified PBD 16, and the mixture of 
16/17, were non-cytotoxic at concentrations of up to 100 µM 
(the maximum concentration tested), consistent with the 
absence of the electrophilic N10-C11 imine moiety and an 
inability to react covalently with DNA. The lack of cytotoxicity for 
both 16 and 17 provides further evidence for the importance of 
the N10-C11 imine for the biological activity of PBD molecules. 
Table 1 Investigation of the use of various ketones and different bases for the 
formation of 16 and 17.  
Ketone Base  Adduct 
Formation 
Yield (%) 
Acetone Pyrrolidine Yes 67 
Acetone Piperidine Yes 16 
Acetone TMP No N/A 
Acetone Diethylamine No N/A 
Acetone Morpholine No N/A 
Butan-2-one Pyrrolidine No N/A 
Pentan-3-one Pyrrolidine No N/A 
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Table 2 Cytotoxicity of the unmodified PBD (10) and the C11-acetone adducts 
(16 and 17) in the MDA-MB-231 breast tumour cell line.  
Compound IC50 (µM)a 
10 6.67 (±1.08) 
16 >100 
16 & 17  (1:1) >100 
aCytotoxicity toward the MDA-MB-231 breast tumour cell line measured using an 
MTT assay after 48 hours incubation.  
 
In summary, the formation of C11-acetone adducts of PBD 
molecules is reported, most likely mediated through a Stork 
enamine-type mechanism.  Interest in PBDs as therapeutic agents 
has increased in recent years due to the development of highly 
potent PBD-based transcription factor inhibitors14 and Antibody-
Drug Conjugates (ADCs) containing PBD-based payloads4, 5, 28.  
Therefore, the observation reported here that a biologically 
inactive C11-acetone adduct can form during chromatographic 
purification has potential implications for the manufacture of 
PBD-based therapeutic agents. Awareness of the possibility of 
this reaction may allow its prevention by using alternative 
amines to pyrrolidine for protecting group removal during the 
final synthetic steps. From a medicinal chemistry perspective, 
development of novel non-DNA-interactive PBD-based libraries 
could also be produced through this reaction for other purposes.  
Finally, the cytotoxicity evaluation carried out on compounds 16 
and 17 provides further evidence for the importance of the N10-
C11 imine functionality for the biological activity of PBDs.  
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